These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 4117647

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C, Agnoli A, Casacchia M, Reitano M, Ruggieri S, Barba C, Volante F.
    Z Neurol; 1972; 202(4):347-55. PubMed ID: 4117654
    [No Abstract] [Full Text] [Related]

  • 28. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD, Duvoisin RC, Mendoza MR, Schear MJ, Barrett RE.
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Long-term effects of levodopa in the severely disabled patient.
    Sacks OW, Messeloff CR, Schwartz WF.
    JAMA; 1970 Sep 28; 213(13):2270. PubMed ID: 5468938
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor.
    Papavasiliou PS, Cotzias GC, Düby SE, Steck AJ, Fehling C, Bell MA.
    N Engl J Med; 1972 Jan 06; 286(1):8-14. PubMed ID: 4550085
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U, Schönfelder H.
    Nervenarzt; 1972 Oct 06; 43(10):531-2. PubMed ID: 4628192
    [No Abstract] [Full Text] [Related]

  • 40. [Collateral effects of L-dopa treatment in patients with parkinsonism].
    Signorelli CD, D'Andrea F, De Divitiis E.
    Sist Nerv; 1970 Oct 06; 22(2):109-14. PubMed ID: 5504548
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.